KEGG   DRUG: Icrucumab
Entry
D09926                      Drug                                   
Name
Icrucumab (USAN/INN)
Formula
C6514H10024N1756O2032S42
Exact mass
146704.3296
Mol weight
146794.64
Sequence
(Heavy chain)
QAQVVESGGG VVQSGRSLRL SCAASGFAFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYY
ADSVRGRFTI SRDNSENTLY LQMNSLRAED TAVYYCARDH YGSGVHHYFY YGLDVWGQGT
TVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP
AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA
PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT
VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY GASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPLTFG GGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H96, H153-H209, H270-H330, H376-H434, H235-H'235, H238-H'238, L23-L89, L135-L195, H229-L215)
  Type
Peptide
Efficacy
Antineoplastic, Angiogenesis inhibitor, Anti-vascular endothelial growth factor receptor-1 antibody
  Type
Monoclonal antibody
Comment
Treatment of solid tumors
Target
VEGFR1 (FLT1) [HSA:2321] [KO:K05096]
  Pathway
hsa04066  HIF-1 signaling pathway
hsa04510  Focal adhesion
Brite
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   VEGFR family
    VEGFR1 (FLT1)
     D09926  Icrucumab (USAN/INN)
Other DBs
CAS: 1024603-92-6
PubChem: 124490620
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system